gold stocks postpage LB desk

The A2 Milk’s Revenue Grew Over 40% In The First Four Months Of FY19

  • November 20, 2018 10:12 AM AEDT
  • Team Kalkine
The A2 Milk’s Revenue Grew Over 40% In The First Four Months Of FY19

The a2 Milk Company traded at lower levels on the day of its Annual General Meeting. A2M’s share price fell by 1.224% or $0.120 to close at $9.680 on 20 November 2018.

non AMP MTF 10th feb webinar

Under the leadership of new Chief executive officer Jayne Hrdlicka, the a2 Milk’s revenue jumped 40.5% to NZ$368.4 million in the first four months of Fiscal 2019, compared to the previous corresponding period. This reflects the strong infant formula sales experienced by the company across all its stages and channels.

As per the company’s information, China MBS distribution increased from approximately 10,000 to approximately 12,000 stores while US distribution increased from 6,000 to approximately 9000 stores.Â

Earnings before interest, tax, depreciation and amortization (EBITDA) grew by 58.5% to NZ$124.2 million for the four months to October 2018. It led unaudited net profit after tax (NPAT) of the company to increase from NZ$52.3 million in 4M FY18 to NZ$86.0 million in 4M FY19, outlining 64.5% improvement on the previous corresponding period.

The A2 Milk’s financial results for FY18 delivered strong results with Group Revenue of $922.7 million , a 68% increase over prior year; EBITDA of $283.0 million, double the fiscal year 2017; Net Profit after tax of $195.7 million up 116% on the previous corresponding period; strong cash conversion with operating cash flow of $231.1 million, an increase of 131%; and, importantly, record market share positions across all key products in all regions.

Further, the company has witnessed continued momentum in its China business that led China label infant formula sales to grow by over 75% on the same four months last year. Moreover, it has been reported that China MAT value share increased to 5.6% in Kantar consumption, compared to 5.1% as at FY18 end.

CEO Ms. Hrdlicka stated a2 Platinum® infant formula, which has been ranked number two brand in CBEC infant formula, remains the market leader with ~33% share up from ~32% share at the end of FY18.

On FY19 outlook, the company expects strong revenue growth to continue but at a slightly more moderate rate than in the first four months of Fiscal 2019. EBITDA to sales ratio is expected to broadly consistent with FY18 reflecting a higher gross margin percentage. But it is forecasted to be offset by Increased marketing expenditure as a percentage of sales given continued investment in the Australian market and an increased investment to support China and US market expansion – phasing will be higher in 2H19; further investment in greater resourcing to support continued growth; and the favourable impact of forex in the first four month forecasted to reverse during the balance of the year.

The a2 Milk Company Limited (ASX: a2M) is recognized as multinational company that operates its business across New Zealand, Australia, China, the USA and the UK. a2M stock last traded at $9.680 with market capitalization of $7.19 billion as on 20 November 2018. Moreover, the stock has witnessed a performance change of attractive 38.61% over the past one year.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.



The website is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK